Form 4: OraSure Director Nancy Gagliano Awarded 46,106 Shares

OraSure Technologies Director Nancy J. Gagliano received a grant of 46,106 restricted shares as part of the company's annual equity compensation plan.

Summary

• Nancy J. Gagliano, a member of the Board of Directors, was granted 46,106 restricted shares of common stock on June 3, 2026.
• The shares were granted at no cost ($0.00) as part of the OraSure Technologies, Inc. Stock Award Plan.
• Following this transaction, Gagliano's total direct ownership in the company increased to 185,055 shares.
• The restricted shares are scheduled to vest in full on June 3, 2027, or immediately prior to the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive administrative event that confirms director alignment with shareholders without signaling a change in corporate strategy.

Positives

• Director ownership has increased to 185,055 shares, further aligning board interests with those of common shareholders.
• The one-year vesting requirement encourages director retention and long-term commitment to the company.

Negatives

• The grant represents potential future dilution of existing shares, though it is a standard part of corporate compensation.

Risks

• Vesting is contingent upon continued service; shares are forfeited if the director voluntarily leaves the board before the vesting date.

Future Outlook

The granted shares will vest in full by June 2027, provided the director remains on the board, ensuring continued governance stability through the next annual meeting cycle.

Management Comments

• Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors.

Industry Context

StockSavvy.ai notes that equity-based compensation for non-employee directors is a standard industry practice among medical diagnostic companies to ensure board members maintain a vested interest in the company's long-term stock performance.

Comparison to Industry Standards

• The grant of restricted stock units is consistent with compensation structures at peer companies such as QuidelOrtho and Meridian Bioscience.
• A one-year cliff vesting period is the standard benchmark for annual director equity awards in the Russell 2000 healthcare sector.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from directors having significant 'skin in the game' through increased share ownership.

Next Steps

• Full vesting of the 46,106 shares on June 3, 2027.
• Participation in the 2027 Annual Meeting of Stockholders.

Key Dates

Recommendation

This filing reflects a routine compensation event for a director and does not provide new material information regarding the company's operational performance or financial health that would warrant a change in investment rating.

Keywords

OraSure Technologies, OSUR, Insider Trading, Form 4, Director Compensation, Restricted Stock, Nancy Gagliano, Equity Grant